Trial Number

692-16

Condition

Leukemia

Participant Age Range

1 Year to 21 Years

Participant Gender

Any

Enrolling Participants

Yes

Overview

INCB 18424-269: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With DeNovo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia (AALL1521)

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.